Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
Key Highlights
- ➤November 10 webcast will present updated Phase 2 silevertinib data
- ➤FDA feedback supports a Phase 3 path toward potential accelerated approval
- ➤Over 200 patients with EGFRm NSCLC or EGFR-altered GBM treated with silevertinib
- ➤Silevertinib targets classical and more than 50 non-classical EGFR mutations
- ➤Randomized Phase 2 GBM trial is underway in newly diagnosed EGFRvIII-positive patients
Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET.
Get started
Create a free account to read the full story.